IMB 1004
Alternative Names: IMB-1004Latest Information Update: 19 Oct 2023
At a glance
- Originator IMIDomics
- Class Anti-inflammatories; Monoclonal antibodies
- Mechanism of Action Natural killer cell inhibitors; T lymphocyte inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research Crohn's disease; Systemic lupus erythematosus; Ulcerative colitis
Most Recent Events
- 11 Oct 2023 IMB 1004 is available for licensing as of 13 Oct 2023. https://www.imidomics.com/partnerships
- 11 Oct 2023 IMIDomics in-licenses innovative drug development technology from University of Barcelona
- 11 Oct 2023 Early research in Crohn's disease in Spain (Parenteral) (IMIDomics pipeline, October 2023)